目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Insomnia - Overview
Insomnia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Insomnia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insomnia - Companies Involved in Therapeutics Development
Insomnia - Drug Profiles
Insomnia - Dormant Projects
Insomnia - Discontinued Products
Insomnia - Product Development Milestones
Featured News & Press Releases
Jul 21, 2022: Zelira's Zenivol, the World's first clinically validated cannabinoid medication for insomnia, achieves regulatory approval in Germany
Jul 19, 2022: Idorsia announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as patient ambassador for QUVIVIQ (daridorexant), a Once Nightly Treatment for Insomnia
Jul 13, 2022: Zenivol reaches significant milestone by receiving formal federal regulatory authority (BFARM) approval in Germany
Jun 08, 2022: Eisai to present latest data on lemborexant at the 36th Annual SLEEP 2022 Meeting
May 13, 2022: Idorsia U.S. announces first wave of patients prescribed QUVIVIQ (daridorexant) through partnership with pharmacy services provider
May 10, 2022: First patients enrolled for Schedule 3 CBD clinical trial for Australian Pharmacy Market
May 03, 2022: Europe's first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder
May 02, 2022: Idorsia's new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
Mar 10, 2022: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy - to be presented at World Sleep 2022
Feb 25, 2022: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder
Jan 20, 2022: The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
Jan 10, 2022: Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
Jan 10, 2022: Idorsia presents at the 40th J.P. Morgan Healthcare Conference - Ready for first product launches - QUVIVIQ (daridorexant) approved by the US FDA
Dec 08, 2021: Results for phase I human clinical trial characterising CBD absorption from Avecho's soft-gel capsule
Oct 04, 2021: Dosing commences for phase I human clinical trial measuring CBD absorption in healthy volunteers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us

List of Tables
Number of Products under Development for Insomnia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Insomnia - Dormant Projects, 2022
Insomnia - Dormant Projects, 2022 (Contd..1)
Insomnia - Dormant Projects, 2022 (Contd..2)
Insomnia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Insomnia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Disclaimer